1 Ocak 2019 Dergi makalesi Açık Erişim

Sipahi, Savas; Genc, Ahmed Bilal; Acikgoz, Seyyid Bilal; Yildirim, Mehmet; Aksoy, Yakup Ersel; Vatan, Mehmet Bulent; Dheir, Hamad; Altindis, Mustafa

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Sipahi, Savas</dc:creator>
  <dc:creator>Genc, Ahmed Bilal</dc:creator>
  <dc:creator>Acikgoz, Seyyid Bilal</dc:creator>
  <dc:creator>Yildirim, Mehmet</dc:creator>
  <dc:creator>Aksoy, Yakup Ersel</dc:creator>
  <dc:creator>Vatan, Mehmet Bulent</dc:creator>
  <dc:creator>Dheir, Hamad</dc:creator>
  <dc:creator>Altindis, Mustafa</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description>INTRODUCTION In patients undergoing haemodialysis, cardiovascular mortality and morbidity, characterised by accelerated atherosclerosis and increased inflammation, are elevated. Salusins are newly defined molecules in the atherosclerotic processes, and while salusin-alpha (Sal-alpha) acts as an antiatherogenic factor, salusin-beta (Sal-beta) has a proatherogenic role. Their roles are as yet undefined in patients undergoing haemodialysis.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/67549</dc:identifier>
  <dc:identifier>oai:zenodo.org:67549</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>SINGAPORE MEDICAL JOURNAL 60(4) 210-215</dc:source>
  <dc:title>Relationship of salusin-alpha and salusin-beta levels with atherosclerosis in patients undergoing haemodialysis</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>